Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
476.3 CHF | -0.36% | +3.73% | +34.46% |
Mar. 05 | Lonza, Epsilogen Report GMP Manufacturing of Ovarian Cancer Antibody | MT |
Feb. 06 | LONZA GROUP : Some mixed real-world effects |
Sales 2023 | 6.72B 7.55B | Sales 2024 * | 6.61B 7.43B | Capitalization | 35.51B 39.92B |
---|---|---|---|---|---|
Net income 2023 | 654M 735M | Net income 2024 * | 885M 995M | EV / Sales 2023 | 4.05 x |
Net Debt 2023 | 922M 1.04B | Net Debt 2024 * | 2.2B 2.47B | EV / Sales 2024 * | 5.71 x |
P/E ratio 2023 |
39.8
x | P/E ratio 2024 * |
38.9
x | Employees | 18,000 |
Yield 2023 |
1.13% | Yield 2024 * |
0.95% | Free-Float | 96.94% |
Latest transcript on Lonza Group AG
1 day | -0.49% | ||
1 week | +4.32% | ||
Current month | +3.46% | ||
1 month | +4.57% | ||
3 months | +39.60% | ||
6 months | +12.66% | ||
Current year | +35.14% |
Managers | Title | Age | Since |
---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 17-04-24 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 21-11-30 |
Maria Nunez
COO | Chief Operating Officer | 55 | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 14-04-15 |
Director/Board Member | 66 | 14-04-15 | |
Marion Helmes
BRD | Director/Board Member | 58 | 22-05-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.53% | 2 M€ | -.--% | ||
3.83% | 121 M€ | -.--% | - | |
1.77% | 18 M€ | +5.16% | - | |
1.74% | 7 M€ | -.--% | - | |
0.95% | 49 M€ | +4.70% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 475.7 | -0.48% | 37 246 |
24-03-18 | 478 | +0.84% | 148,453 |
24-03-15 | 474 | -1.92% | 577,590 |
24-03-14 | 483.3 | +2.57% | 284,081 |
24-03-13 | 471.2 | +2.77% | 253,304 |
Delayed Quote Swiss Exchange, March 18, 2024 at 12:31 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.14% | 40.04B | |
+9.72% | 46.21B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B | |
+6.40% | 11.01B |